4/A

PRIMARY DOCUMENT

Company: Syndax Pharmaceuticals Inc
Filed: March 25, 2019
Period of Report: March 21, 2019
Accession Number: 0001562180-19-002023

View Document ↗ View on SEC.gov ↗